Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 13,095 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 13,095 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $5.81, for a total transaction of $76,081.95. Following the sale, the insider directly owned 770,495 shares of the company’s stock, valued at $4,476,575.95. This represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The shares were sold at an average price of $5.73, for a total transaction of $23,005.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total transaction of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $42,830.37.
• On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The shares were sold at an average price of $6.32, for a total transaction of $21,172.00.
• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total value of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total value of $28,560.18.
• On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The shares were sold at an average price of $6.45, for a total value of $36,003.90.
• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total value of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total value of $36,815.28.

Clene Stock Down 1.7%

Clene stock opened at $5.77 on Friday. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50. The business’s 50-day moving average price is $8.06 and its two-hundred day moving average price is $6.34. The stock has a market cap of $59.60 million, a PE ratio of -1.70 and a beta of 0.87.

Clene (NASDAQ:CLNN) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. As a group, analysts expect that Clene Inc. will post -5.19 earnings per share for the current year.

Hedge Funds Weigh In On Clene

A number of hedge funds have recently made changes to their positions in CLNN. Jones Financial Companies Lllp acquired a new position in shares of Clene in the third quarter worth approximately $29,000. Jane Street Group LLC acquired a new position in shares of Clene in the 2nd quarter worth approximately $47,000. Lunt Capital Management Inc. boosted its stake in shares of Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares during the last quarter. Finally, Scoggin Management LP increased its position in shares of Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after buying an additional 42,750 shares during the period. 23.28% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CLNN. Benchmark reiterated a “buy” rating on shares of Clene in a report on Thursday, December 4th. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of Clene in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a research report on Tuesday, October 14th. Finally, UBS Group reissued a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Clene has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).